GSK360A

Cat. No.: HY-123422

CAS No.: 931399-19-8

Molecular Formula: $C_{17}H_{17}FN_2O_5$

Molecular Weight: 348.33

Target: HIF/HIF Prolyl-Hydroxylase

Pathway: Metabolic Enzyme/Protease

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

GSK360A is a potent and orally active HIF-PHD inhibitor with IC_{50} values of 10, 100, and 126 nM for PHD1, PHD2, and PHD3, respectively. GSK360A activates the HIF-1 alpha pathway and protect the failing heart after myocardial infarction (MI) [1].

In Vivo

GSK360A (30 mg/kg i.g.) improves long-term ventricular function, remodeling, and vascularity in a model of established ventricular dysfunction[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	male Lewis rats with ventricular dysfunction model[1]
Dosage:	30 mg/kg
Administration:	oral gavage
Result:	Increased circulating levels of erythropoietin and hemoglobin and hemoxygenase-1 expression in the heart and skeletal muscle of male rats.

REFERENCES

[1]. Bao W, et, al. Chronic inhibition of hypoxia-inducible factor prolyl 4-hydroxylase improves ventricular performance, remodeling, and vascularity after myocardial infarction in the rat. J Cardiovasc Pharmacol. 2010 Aug;56(2):147-55.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA